Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury.
about
Stimulating healthy tissue regeneration by targeting the 5-HT₂B receptor in chronic liver disease.Homing in on the hepatic scar: recent advances in cell-specific targeting of liver fibrosisTherapeutic targeting of redox signaling in myofibroblast differentiation and age-related fibrotic diseaseMeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis.Hepatic fibrosis.Macrophages: master regulators of inflammation and fibrosis.The PXR is a drug target for chronic inflammatory liver disease.Fibrosis: recent advances in myofibroblast biology and new therapeutic perspectives.The functional role of reactive stroma in benign prostatic hyperplasia.Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophagesReversibility of Stricturing Crohn's Disease-Fact or Fiction?Low affinity glucocorticoid binding site ligands as potential anti-fibrogenics.Current and future anti-fibrotic therapies for chronic liver disease.Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies.Targeted RNA interference for hepatic fibrosis.Role of nuclear factor kappaB in liver health and disease.Therapeutic targets in liver fibrosis.Myofibroblast differentiation and survival in fibrotic disease.Cellular and molecular mechanisms of chronic inflammation-associated organ fibrosis.A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice.Keratinocyte-derived chemokine induces prostate epithelial hyperplasia and reactive stroma in a novel transgenic mouse model.Hepatic stellate cells regulate liver immunity to visceral leishmaniasis through P110δ-dependent induction and expansion of regulatory T cells in mice.A new fluorescence-based optical imaging method to non-invasively monitor hepatic myofibroblasts in vivoTargeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy.A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A.Resolution of organ fibrosis.Intestinal Fibrosis and Liver Fibrosis: Consequences of Chronic Inflammation or Independent Pathophysiology?
P2860
Q24610679-F7D86CF8-579F-485A-83A2-673CD48963B7Q26742049-41F19841-4043-4E8F-A6D9-134A01E5E12FQ26827629-A639C0D5-FC30-402C-956F-267E51A60F4CQ33643242-98A10D7E-A26F-4093-A99C-554041C857D4Q33904174-CBDE596C-D985-45C1-A216-71863269D087Q34076279-07D76CFF-6760-4F24-BC2C-670BB821F878Q34118368-D152D890-528D-425A-9604-30E8944BD30AQ34389512-D953D9E6-A270-4D76-B375-06CE6976FE69Q35231687-C2619295-A752-4758-8CFE-B77EA215A6DFQ35825861-310D180B-6259-49D7-8FFD-B57B95BEF399Q36373253-35623D5B-D3AC-49F9-8E0C-CD2E95842B24Q37207594-2CDA6F52-645B-47DE-95E8-C17D2C0B61E5Q37317654-36C87027-F5BE-4FEA-A1F9-7E7D8D10599EQ37355850-3FA79978-1F44-46DA-B129-64F1F2BF9905Q37590368-87B076CE-16B9-47C0-85BA-81D11B7F914FQ37720780-AE156AEE-6273-48C0-84D9-7908EF5185F9Q37828321-19967C71-32CD-4523-A0B0-537312E5FD4DQ37921386-91F4E0B3-4C8B-4070-875C-7D1F25E94AA3Q38008371-1A93750F-B741-48D4-8393-515B49DB3CD4Q39282703-71184F56-950B-485B-9F72-64678299BDDBQ39914178-AE5CDCEE-4246-4C14-A6CF-BA95FCC2A0C3Q41043666-86B3E79E-3F1C-4E22-9CEE-5765C5276519Q42578817-EB9C512D-2D82-4E69-89B0-289C452DA4FFQ42591676-C86CB907-F5E8-4D47-AA09-E21AF835AA16Q45864008-3D4A5F3C-4006-4A1A-AC07-118AFB506E94Q52687459-59683EAD-C470-4A0C-A902-0190E76EAD20Q55262881-2208556C-779A-4A31-9C51-99E58F4C840C
P2860
Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury.
@en
Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury.
@nl
type
label
Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury.
@en
Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury.
@nl
prefLabel
Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury.
@en
Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury.
@nl
P2093
P1476
Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury
@en
P2093
Andrew J Porter
Angela Douglass
Caroline Barelle
Elaine Durward
Jennifer Park
Karen Wallace
Rebecca Parr
P356
10.1016/J.JHEP.2008.01.032
P577
2008-03-13T00:00:00Z